

# United Spirits

**BSE SENSEX** 48,093  
**S&P CNX** 14,137

## UNITED SPIRITS

A DIAGEO Group Company

Bloomberg	UNSP IN
Equity Shares (m)	727
M.Cap.(INRb)/(USDb)	445.9 / 5.8
52-Week Range (INR)	743 / 443
1, 6, 12 Rel. Per (%)	-2/-28/-9
12M Avg Val (INR M)	1807

### Financials & Valuations (INR b)

Y/E March	2020	2021E	2022E	2023E
Sales	90.9	84.2	98.5	108.6
Sales Gr. (%)	1.2	-7.4	17.0	10.3
EBITDA	15.1	10.6	16.4	20.4
Margin (%)	16.6	12.6	16.6	18.8
PAT	7.9	4.9	9.7	12.9
EPS (INR)	10.9	6.7	13.3	17.7
EPS Gr. (%)	16.9	-38.6	99.6	32.7
BV/Sh.(INR)	52.4	58.0	71.4	89.1

### Ratios

RoE (%)	20.8	11.5	18.7	19.9
RoCE (%)	17.3	18.4	26.0	27.3
Payout (%)	0.0	0.0	0.0	0.0

### Valuations


P/E (x)	56.4	91.8	46.0	34.7
P/BV (x)	11.7	10.6	8.6	6.9
EV/EBITDA (x)	30.4	42.4	27.1	3.6

### Shareholding pattern (%)

As On	Sep-20	Jun-20	Sep-19
Promoter	56.8	56.8	56.8
DII	9.2	9.4	7.9
FII	18.8	19.7	22.4
Others	15.2	14.2	12.9

FII Includes depository receipts

### Stock Performance (1-year)



**CMP: INR614** **TP: INR750 (+22%)** **Upgrade to Buy**

## Raising a toast to growth – upgrade to Buy

We believe United Spirits (UNSP)'s prospects are favorable owing to the following factors.


- **Sharper-than-expected recovery; likely to sustain** – Sharp excise increases were seen over Apr–May'20 amid the COVID outbreak, leading to the expectation of a nosedive in sales and volumes. However, in a positive surprise, the company witnessed a strong recovery in 2QFY21, driven by robust in-home consumption. With various occasions of indulgence restricted (outdoor social activity, cinemas, and travel and tourism), spirits offered a convenient alternative for in-home consumption. Accordingly, after 49% volume decline YoY in the lockdown impacted 1QFY21, volume decline was arrested to just 3.9% in the 2QFY21. Hence, we expect volume growth in the positive territory in 3QFY21.
- **Continued high off-trade sales likely to favor spirit players** – On-trade sales (20–25% of total sales) are not likely to normalize anytime soon, particularly with 50% capacity restriction. The bulk of sales is still contributed by in-home consumption. Therefore, spirit players stand to benefit as spirits are more suitable for in-home consumption than beer. Accordingly, visibility for the next few quarters is much better for spirit companies (v/s beer companies) – UNSP is the largest listed player among the spirit players. The stark difference in volumes (reflected in ~4% volume decline for UNSP v/s ~48% decline for UBBL in 2QFY21) is likely to be a feature in FY22 as well. Furthermore, the crucial summer season demand for beer (1QFY22) – a quarter that contributes ~40% to full-year EBITDA for UBBL – is unlikely to achieve normal levels due to the drag on the on-trade channel.
- **Return of premiumization gradually narrowing gap v/s Pernod Ricard's margins** – Premiumization was back in the game from 2QFY21, with the Prestige and Above (P&A) segment reporting slower decline v/s the Popular segment following nearly equivalent decline in 1QFY21. We believe the gap between the two segments would remain significant even when growth resumes. EBITDA margins at 16.6% in FY20 are still a long way from the mid-20% margins of the unlisted Pernod Ricard India (PRI), which operates entirely in the P&A segment. As the P&A segment's share in UNSP's revenues (65% in FY20) keeps on increasing, the margin gap with PRI would continue to narrow.
- **Commendable historical earnings track record** – UNSP's sales CAGR of ~3% in the last five years has been below expectations. However, EBITDA/PBT/PAT CAGR has been quite strong at ~18%/~39%/33% over this period. As the margin gap with Pernod Ricard narrows and debt repayments continue, earnings growth is likely to be healthy at a 17% CAGR over FY20–23E. Notably, this comes despite the sharp COVID impact seen in 1HFY21, which resulted in net loss for the period as EBITDA declined 76% YoY.

- **Benign material costs, contrary to fears** – Contrary to fears of sharp escalation in 2HFY21, molasses cost continued to be benign in 3QFY21, with a likely benign outlook as well.
- **No material working capital impact; debt repayment on track** – With state finances affected due to COVID, we anticipated an increase in receivable days. As this has fortunately not played out, there has been no material deterioration in working capital. At the same time, debt repayment, a key factor for earnings growth in the last five years, continues unhinged.
- **Underperforming stock; inexpensive relative valuations** – Since our [downgrade to Neutral in May'20](#), UNSP has been the worst performer among discretionary stocks. Valuations, on the other hand, are at a 25% discount to our Coverage Universe at 46x FY22 EPS and 34.7x FY23 EPS. With an improving outlook, we upgrade UNSP to BUY, with TP of INR750, valuing the company at 45x Dec'22 EPS.

### Sharper-than-expected recovery

- Sharp excise increases seen over Apr–May'20, amid the COVID outbreak, led to expectations of a plunge in the sales and volumes of UNSP. However, contrary to fears, volume growth in spirits has recovered strongly, led by in-home consumption. With various occasions of indulgence restricted (outdoor social activity, cinemas, and travel and tourism), spirits offered a convenient alternative for in-home consumption. Furthermore, spirit players benefited more (v/s beer companies) as a) spirits do not require refrigeration, unlike beer, and b) beer is consumed more socially and in a group, but spirits not necessarily so. Accordingly, after 49% volume decline YoY in the lockdown impacted 1QFY21, volume decline was arrested to just 3.9% in the 2QFY21. Hence, we expect volume growth in the positive territory in 3QFY21.

**Exhibit 1: UNSP's volumes declined sharply due to COVID-led lockdown, but are expected to recover in the coming quarters**



Source: Company, MOFSL

- We note that the base is highly favorable from 3QFY21.
- Various states have also reduced the extent of effective excise increase in recent months.

## Timeline of excise increases

### A. Pre-COVID escalation

- **12<sup>th</sup> Feb:** Goa increased rates by ~30%, with a consequent price increase of around 25%. We reckon Goa contributes 3–4% to UNSP and UBBL's sales. Despite this increase, excise in Goa continues to be among the lowest in India.
- **6<sup>th</sup> Mar:** Karnataka increased excise by 6% ([news link](#)). Subsequently, companies took a similar price increase. We reckon Karnataka contributes 25% to UNSP's sales and 14% to UBBL's sales.

### B. During the COVID-led lockdown


- **30<sup>th</sup> Apr:** Rajasthan announced a 10% excise increase and allowed a price rise of 10% ([news link](#)). We reckon the state contributes 3–4% to the sales of both UBBL and UNSP.
- **3<sup>rd</sup> May:** Haryana announced it would consider increasing excise duty, but it is yet to decide on the quantum ([news link](#)).
- **4<sup>th</sup> and 5<sup>th</sup> May:** Andhra Pradesh announced an effective 75% increase in excise over two days ([news link](#)). We reckon the state contributes 4% to the sales of UNSP and 6% to the sales of UBBL. The price increase is yet to be determined.
- **4<sup>th</sup> May:** Delhi announced 70% COVID cess on liquor ([news link](#)). An effective price increase is yet to be determined. We reckon Delhi contributes around 3% to the nationwide sales of UBBL and UNSP.

### C. Post the COVID-19 unlock


- **7<sup>th</sup> Jun:** The Delhi government has decided to withdraw the special COVID fee levied at 70% on MRP ([news link](#)), which it had placed on the sale of all types of liquor in the state.
- **24<sup>th</sup> Oct:** States that had imposed a tax of 25% and above in the wake of COVID are likely to end up with lower tax revenue from liquor sales and also collect less tax per bottle due to consumer downtrading, the Confederation of Indian Alcoholic Beverage Companies (CIABC) stated ([news link](#)).
- **5<sup>th</sup> Nov:** Under the new excise policy of West Bengal, the rate of excise duty and additional excise duty would depend on the ex-distillery price (EDP) of the liquor instead of excise duty and sales tax being levied on MRP ([news link](#)).

## Continued high off-trade sales likely to favor spirit players

- **On-trade sales** (20–25% of sales) are not likely to normalize anytime soon, particularly with 50% capacity restrictions. The bulk of sales is still contributed by in-home consumption. Therefore, spirit players stand to benefit as spirits are more suitable for in-home consumption than beer. Accordingly, there is much better visibility for spirit companies over the next few quarters v/s beer companies – UNSP is the largest listed spirit player.
- **The stark difference in volumes** (reflected in 4% volume decline for UNSP v/s 48% decline for UBBL in 2QFY21) is likely to be a feature in FY22 as well. Furthermore, crucial summer season demand for beer (1QFY22) – a quarter that contributes ~40% to full-year EBITDA for UBBL – is unlikely to achieve normal levels due to the drag on the on-trade channel. Vaccination for the masses is not scheduled to begin until Aug'21 as the focus would initially be on the most vulnerable 20% of the population.

**Exhibit 2: UNSP's volumes were affected by the lockdown...**

Source: Company, MOFSL


**Exhibit 3: ...but the impact was much lower than that on UBBL's volumes**

Source: Company, MOFSL


**Exhibit 4: UNSP is expected to significantly outperform alcobev peer UBBL**

INR m	FY2020	FY2023E	CAGR % (2020–23E)
<b>UNSP</b>			
Volumes (mn cases)	79.8	91.2	4.6
Sales	90,565	1,08,152	6.1%
EBITDA	15,081	20,423	10.6%
PAT	7,909	12,866	17.6%
<b>UBBL</b>			
Volumes (mn cases)	176.3	167.5	(1.7)
Sales	65,092	66,400	0.7
EBITDA	8,758	9,820	3.9
PAT	4,277	4,160	-0.9


Source: Company, MOFSL

**Exhibit 5: 1Q has a higher contribution to UBBL's annual sales...**

Source: MOFSL, Company

**Exhibit 6: ...and even higher to EBITDA (v/s UNSP)**

Source: MOFSL, Company


**Exhibit 7: RoE and RoCE for UNSP are likely to recover rapidly post the 1HFY21 impact**

Source: Company, MOFSL

### Return of premiumization gradually narrowing gap v/s Pernod Ricard's margins


- Premiumization was back in the game from 2QFY21, with the P&A segment reporting slower decline v/s the Popular segment following nearly similar declines in 1QFY21. We believe the gap between the two segments would remain significant even when growth resumes. EBITDA margins at 16.6% in FY20 are still a long way from the mid-20% margins of the unlisted Pernod Ricard India (PRI). As P&A's share in revenues (65% in FY20) keeps on increasing, the margin gap with PRI would continue to narrow. PRI operates entirely in the P&A segment.
- Additionally, the management commentary on premiumization within the P&A category is also encouraging. Management had indicated that the P&A segment is likely to see the return of the trend wherein each premium category grows at a faster pace (or declines at a slower pace) than the one ranked immediately below it. While this had played out in 2QFY21, the trend is expected to continue going forward.

### Exhibit 8: P&A's salience in the total sales of UNSP has been steadily increasing



Source: Company, MOFSL


### Exhibit 9: EBITDA margins – UNSP v/s Pernod Ricard India




Source: Company, MOFSL

### Commendable earnings track record


- UNSP's sales CAGR of ~3% in the last five years has been below our expectations. However, the EBITDA/PBT/PAT CAGR has been quite strong at ~18%/~39%/33% over this period. As the EBITDA margin gap with Pernod Ricard narrows and debt repayments continue, earnings growth is likely to be healthy at a 17% CAGR over FY20–23E. Notably, this comes despite the sharp COVID impact in 1HFY21, which resulted in net loss for the period as EBITDA declined 76% YoY.

**Exhibit 10: Sales grew at a CAGR of 2.7% over FY15–20**


Source: Company, MOFSL

**Exhibit 11: EBITDA grew at a CAGR of 17.8% over FY15–20**


Source: Company, MOFSL

**Exhibit 12: PBT grew at a CAGR of 38.8% over FY15–20**


Source: Company, MOFSL

**Exhibit 13: PAT grew at a CAGR of 32.7% over FY15–20**


Source: Company, MOFSL

**Exhibit 14: RoE improved by 1,410bp over FY15–20**


Source: Company, MOFSL

**Exhibit 15: RoCE improved by 890bp over FY15–20**

Source: Company, MOFSL

**Exhibit 16: EBITDA growth is expected to recover sharply...**

Source: Company, MOFSL


**Exhibit 17: ...with PAT growth to follow suit**

Source: Company, MOFSL

### Benign material costs, contrary to fears

- Contrary to fears of a sharp escalation in 2HFY21, molasses cost continued to be benign in 3QFY21, with a likely benign outlook as well.

**Exhibit 18: WPI molasses (up to Nov'20) was up 3.3% YoY, down 2.9% QoQ**




Source: Bloomberg, MOFSL

- The material cost movement for grain-based spirits is also benign.

**Exhibit 19: Wheat prices were down 24.2% YoY / 5.7% QoQ**


Wheat prices (INR/Quintal)



Source: Bloomberg, MOFSL

**Exhibit 20: Barley prices were down 31.6% YoY / up 2.9% QoQ**

NCDEX Barley Spot (INR/quintal)




Source: Bloomberg, MOFSL


- Cost of glass bottles – another large material cost component – is also likely to be benign, according to our conversations with industry players. With the sales mix improving going forward as well, owing to faster growth in P&A, the gross and EBITDA margin trend outlook is positive.

### No material working capital impact; debt repayment on track

- With state finances being affected due to COVID, we anticipated an increase in receivable days. As this has fortunately not played out, there has been no material deterioration in working capital.
- In fact, the amount of trade receivables reduced marginally in Sep'20 v/s Mar'20 levels. At the same time, debt repayments – a key factor for earnings growth in the last five years – continue at a healthy pace.
- There is no large capex plan over the next 2.5 years. Due to legacy issues, the company is in the process of reducing the number of distilleries rather than planning any major greenfield expansion.
- Debt repayments continued to be a feature in 1HFY21. Net debt has reduced significantly over the last two quarters.

**Exhibit 21: UNSP has steadily reduced its debt levels over the years...**

Source: Company, MOFSL

**Exhibit 22: ...consequently reducing its interest burden**

Source: Company, MOFSL

**Underperforming stock; inexpensive relative valuations**

- Since our [downgrade to Neutral in May'20](#), UNSP has been the worst performer among Discretionary stocks..


**Exhibit 23: UNSP's stock has returned 22.5%, v/s an average of 44.5% for our Consumer Universe, since 8<sup>th</sup> May 2020**

Company	08-05-2020	CMP	Change
Emami	182	453	148.9%
Titan Company	833	1,542	85.2%
Jubilant Food.	1,567	2,866	82.9%
Asian Paints	1,578	2,791	76.9%
Page Industries	16,983	28,658	68.7%
Westlife Development	288	445	54.5%
Godrej Consumer	500	735	47.0%
United Breweries	890	1,247	40.1%
Marico	300	418	39.3%
Jyothy Lab.	106	147	38.4%
Pidilite Inds.	1,368	1,773	29.6%
ITC	158	203	28.3%
<b>UNSP</b>	<b>501</b>	<b>614</b>	<b>22.5%</b>
Dabur India	447	536	19.8%
Britannia Inds.	2,995	3,554	18.7%
Colgate	1,360	1,593	17.1%
Hind. Unilever	2,089	2,370	13.4%
P & G Hygiene	10,028	11,237	12.1%
Nestle India	17,803	18,140	1.9%

Source: MOFSL


- Valuations at 46x FY22 EPS and 34.7x FY23 EPS, on the other hand, are at a 25% discount to our Coverage Universe. With an improving outlook, we upgrade UNSP to BUY, with TP of INR750 (22% upside to CMP).

#### Exhibit 24: UNSP has one of the lowest P/E valuations in our Consumer Universe for FY22E...



Source: Company, MOFSL

#### Exhibit 25: ...and even lower for FY23E




Source: Company, MOFSL

### Valuation and view


- Recovery in volumes has been better than we expected, with the company likely to report positive volume growth in 3QFY21E. Higher in-home consumption would favor UNSP, relative to beer players.
- With the return of premiumization in favor of P&A, the company is also back on track to gradually bridge the 800–900bps margin gap between UNSP and Pernod Ricard India. Moreover, prior concerns of higher molasses cost in 2HFY21 are proving unfounded – as molasses costs remained benign in 3QFY21 and industry sources indicate a swift outlook going forward as well.
- Working capital has not worsened, unlike earlier concerns, and debt repayment is on track, with a further sharp reduction seen in 1HFY21.
- The earnings track record has been healthy – with the EBITDA/PBT/PAT CAGR at ~18%/~39%/33% over the past five years – and is likely to be strong going forward as well. Resultantly, the EPS CAGR is likely to be 17% over FY20–23; this is despite the massive lockdown impact leading to net loss in 1HFY21 (as EBITDA declined 76% YoY during this period).
- Since our [downgrade to Neutral in May 2020](#), UNSP has been the worst performer among the Discretionary stocks. Valuations, on the other hand, are at a 25% discount to the Coverage Universe at 46x FY22 EPS and 34.7 FY23 EPS. With an improving outlook, we upgrade UNSP to BUY, with TP of INR750, valuing the company at 45x Dec'22 EPS.

Exhibit 26: UNSP P/E chart



Source: MOFSL, Company

Exhibit 27: Consumer P/E chart



Source: MOFSL, Company

## Financials and valuations

Income Statement								(INR m)
Y/E March	2016	2017	2018	2019	2020	2021E	2022E	2023E
Net Sales	81,886	85,030	81,269	89,322	90,565	83,820	98,078	1,08,152
Other Operating Inc	596	446	432	484	344	400	440	484
Total Revenue	82,482	85,476	81,701	89,806	90,909	84,220	98,518	1,08,636
Change (%)	3.7	3.6	-4.4	9.9	1.2	-7.4	17.0	10.3
Gross Profit	34,076	36,632	39,725	43,857	40,689	36,552	45,318	53,232
Margin (%)	41.3	42.9	48.6	48.8	44.8	43.4	46.0	49.0
Other Expenditure	-25,212	-26,922	-29,446	-30,983	-25,608	-25,974	-28,964	-88,213
EBITDA	8,864	9,710	10,279	12,874	15,081	10,578	16,354	20,423
Change (%)	33.2	9.5	5.9	25.2	17.1	-29.9	54.6	24.9
Margin (%)	10.7	11.4	12.6	14.3	16.6	12.6	16.6	18.8
Depreciation	-1,017	-1,323	-1,351	-1,445	-2,275	-2,434	-2,678	-2,972
Int. and Fin. Charges	-4,469	-3,690	-2,675	-2,200	-1,907	-1,926	-1,348	-1,011
Other Income	1,057	1,111	1,080	952	455	528	633	760
Profit before Taxes	4,435	5,808	7,333	10,181	11,354	6,745	12,961	17,200
Change (%)	101.3	31.0	26.3	38.8	11.5	-40.6	92.1	32.7
Margin (%)	5.4	6.8	9.0	11.3	12.5	8.0	13.2	15.8
Tax	2,358	1,923	2,433	3,416	3,445	1,889	3,266	4,334
Tax Rate (%)	53.2	33.1	33.2	33.6	30.3	28.0	25.2	25.2
Adjusted PAT	2,076	3,884	4,900	6,765	7,909	4,857	9,695	12,866
Change (%)	8.1	87.1	26.1	38.1	16.9	-38.6	99.6	32.7
Margin (%)	2.5	4.5	6.0	7.5	8.7	5.8	9.8	11.8
Non-rec. (Exp)/Income	-858	-2,186	717	-179	-862	-750	0	0
Reported PAT	1,219	1,699	5,617	6,586	7,047	4,107	9,695	12,866
Balance Sheet								(INR m)
Y/E March	2016	2017	2018	2019	2020	2021E	2022E	2023E
Share Capital	1,453	1,453	1,453	1,453	1,453	1,453	1,453	1,453
Reserves	15,687	17,925	23,585	29,862	36,644	40,693	50,388	63,253
Net Worth	17,140	19,378	25,038	31,315	38,097	42,146	51,841	64,706
Loans	37,082	40,407	32,505	25,825	15,195	6,695	4,695	3,695
Deferred Tax Liabilities	-1,539	-1,241	-856	-1,878	-1,590	-1,590	-1,590	-1,590
Capital Employed	52,683	58,544	56,687	55,262	51,702	47,251	54,946	66,811
Gross Block	17,389	14,091	13,561	16,406	19,315	19,815	21,315	23,815
Less: Accum. Depn.	-6,627	-2,219	-3,540	-5,124	-5,968	-8,402	-11,080	-14,052
Net Fixed Assets	10,762	11,872	10,021	11,282	13,347	11,413	10,235	9,763
Capital WIP	2,449	851	980	1,171	1,187	1,187	1,187	1,187
Investments	93	3,238	2,775	2,984	2,526	3,476	5,776	4,026
Curr. Assets, L&A	67,082	70,763	71,778	69,308	66,895	67,456	78,063	87,604
Inventory	18,999	18,538	18,694	18,767	18,361	17,686	20,689	22,814
Account Receivables	23,140	29,605	26,998	25,181	22,835	23,074	26,991	28,275
Cash and Bank	3,362	523	1,198	588	345	606	839	5,425
Others	21,581	22,097	24,888	24,772	25,354	26,090	29,544	31,090
Curr. Liab. and Prov.	27,703	28,180	28,867	29,483	32,253	36,281	40,315	35,768
Account Payables	10,018	11,798	13,935	13,360	11,712	13,686	14,726	15,477
Other Liabilities	14,643	13,345	11,490	12,346	16,196	17,816	20,331	14,508
Provisions	3,042	3,037	3,442	3,777	4,345	4,780	5,257	5,783
Net Current Assets	39,379	42,583	42,911	39,825	34,642	31,175	37,748	51,835
Application of Funds	52,683	58,544	56,687	55,262	51,702	47,251	54,946	66,811

E: MOFSL Estimates

## Financials and valuations

### Ratios

Y/E March	2016	2017	2018	2019	2020	2021E	2022E	2023E
<b>Basic (INR)</b>								
<b>EPS</b>	<b>2.9</b>	<b>5.3</b>	<b>6.7</b>	<b>9.3</b>	<b>10.9</b>	<b>6.7</b>	<b>13.3</b>	<b>17.7</b>
Cash EPS	4.3	7.2	8.6	11.3	14.0	10.0	17.0	21.8
BV/Share	23.6	26.7	34.5	43.1	52.4	58.0	71.4	89.1
<b>Valuation (x)</b>								
P/E	214.7	114.8	91.0	65.9	56.4	91.8	46.0	34.7
Cash P/E	144.1	85.6	71.3	54.3	43.8	61.2	36.0	28.2
EV/Sales	1.4	1.4	1.3	1.1	1.0	1.0	0.8	0.7
EV/EBITDA	54.1	49.7	46.2	36.4	30.4	42.4	27.1	3.6
P/BV	26.0	23.0	17.8	14.2	11.7	10.6	8.6	6.9
<b>Return Ratios (%)</b>								
RoE	11.4	21.3	19.6	21.6	20.8	11.5	18.7	19.9
RoCE	6.7	11.4	11.6	14.7	17.3	18.4	26.0	27.3
RoIC	6.7	11.1	11.3	14.9	18.2	13.1	23.0	25.3
<b>Working Capital Ratios</b>								
Asset Turnover (x)	1.6	1.5	1.4	1.6	1.8	1.8	1.8	1.6
<b>Leverage Ratio</b>								
Debt/Equity (x)	2.2	2.1	1.3	0.8	0.4	0.2	0.1	0.1

### Cash Flow Statement

(INR m)

Y/E March	2016	2017	2018	2019	2020	2021E	2022E	2023E
OP/(loss) before Tax	3,155	2,546	8,403	9,914	11,347	6,745	12,961	17,200
Int./Div. Received	1,567	-413	205	1,245	-559	-528	-633	-760
Depreciation and Amort.	1,017	1,323	1,351	1,445	2,275	2,434	2,678	2,972
Interest Paid	3,990	3,488	1,708	1,775	1,626	1,926	1,348	1,011
Direct Taxes Paid	-1,637	-1,943	-3,898	-8,238	-5,658	-1,889	-3,266	-4,334
Incr/Decr in WC	-5,826	1,732	1,694	2,434	-2,361	3,728	-6,339	-9,502
<b>CF from Operations</b>	<b>2,266</b>	<b>6,733</b>	<b>9,463</b>	<b>8,575</b>	<b>6,670</b>	<b>12,417</b>	<b>6,748</b>	<b>6,587</b>
(Incr)/Decr in FA	-2,222	-1,509	41	-656	-1,978	-500	-1,500	-2,500
<b>Free Cash Flow</b>	<b>1,232</b>	<b>5,476</b>	<b>9,621</b>	<b>8,332</b>	<b>6,331</b>	<b>12,445</b>	<b>5,882</b>	<b>4,847</b>
(Pur)/Sale of Investments	8,686	111	213	319	0	-950	-2,300	1,750
Other investing items	2,140	-2,973	1,174	-142	599	-808	0	0
<b>CF from Invest.</b>	<b>9,792</b>	<b>-4,119</b>	<b>1,545</b>	<b>-66</b>	<b>260</b>	<b>-1,730</b>	<b>-3,167</b>	<b>10</b>
Issue of Shares	0	0	0	0	0	0	0	0
Incr/Decr in Debt	-6,606	-3,325	-7,902	-7,004	-5,572	-8,500	-2,000	-1,000
Dividend Paid	0	0	0	0	0	0	0	0
Others	-4,487	-2,128	-2,431	-2,115	-1,601	-1,926	-1,348	-1,011
<b>CF from Fin. Activity</b>	<b>-11,093</b>	<b>-5,453</b>	<b>-10,333</b>	<b>-9,119</b>	<b>-7,173</b>	<b>-10,426</b>	<b>-3,348</b>	<b>-2,011</b>
<b>Incr/Decr of Cash</b>	<b>965</b>	<b>-2,839</b>	<b>675</b>	<b>-610</b>	<b>-243</b>	<b>261</b>	<b>233</b>	<b>4,586</b>
Add: Opening Balance	2,397	3,362	523	1,198	588	345	606	839
<b>Closing Balance</b>	<b>3,362</b>	<b>523</b>	<b>1,198</b>	<b>588</b>	<b>345</b>	<b>606</b>	<b>839</b>	<b>5,425</b>

E: MOFSL Estimates

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

\*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

#### Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on [www.motilaloswal.com](http://www.motilaloswal.com). MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://online.reports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at [www.nseindia.com](http://www.nseindia.com), [www.bseindia.com](http://www.bseindia.com). Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

#### Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

#### For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

#### For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act") and together with the 1934 Act, the "Acts", and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

#### For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

#### Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months
- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
- 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
- 10 MOFSL has not engaged in market making activity for the subject company

\*\*\*\*\*

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

#### Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

#### Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

#### Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website [www.motilaloswal.com](http://www.motilaloswal.com). CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)\*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP000000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: [na@motilaloswal.com](mailto:na@motilaloswal.com), Contact No.:022-71881085.

\* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.